BACKGROUND: A phase II study of @entity2699 ( @entity2699 ), was conducted to determine the response rate, duration of response, @entity137 and overall survival of @entity1 with advanced @entity4292 . @entity1 AND METHODS: Fifty @entity1 with advanced @entity4292 , having progressive symptoms or evidence of rapidly advancing disease were entered on this study. DTIC was given by IV infusion at a dose of 850 mg/m2, over 60-90 minutes, repeated every four weeks. RESULTS: The response rate was 33% in 42 @entity1 who had measurable @entity5 , and 34% in the 50 @entity1 (90% confidence interval (90% CI): 23%-47%). The majority of the responses were seen in @entity1 without prior chemotherapy. Median overall survival was 19.3 months. There were two lethal @entity137 on the study, one @entity326 and one @entity583 . Grade 4 @entity137 were, hematological (5 @entity1 ), @entity295 , neurological ( @entity308 and paranoid behavior) and bleeding (1 @entity1 each). The most common @entity137 was vomiting, grade 3 in 13% of @entity1 . CONCLUSIONS: DTIC has activity in advanced previously untreated @entity4292 .

Phase II trial of XXXX (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity2699 :: ('MESH:D003606', 'Chemical') :: ['dacarbazine', 'DTIC'] @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity4292 :: ('MESH:C535838', 'Disease') :: ['pancreatic islet cell tumors'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']
@entity2699 :: (MESH:D003606,Chemical) :: ['dacarbazine']
